Ieq Capital LLC Makes New Investment in Vanda Pharmaceuticals Inc. $VNDA

Ieq Capital LLC acquired a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 282,779 shares of the biopharmaceutical company’s stock, valued at approximately $1,731,000. Ieq Capital LLC owned approximately 0.47% of Vanda Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Monaco Asset Management SAM acquired a new position in Vanda Pharmaceuticals in the 2nd quarter valued at about $1,354,000. Arrowstreet Capital Limited Partnership purchased a new position in Vanda Pharmaceuticals in the 1st quarter valued at about $1,668,000. AIGH Capital Management LLC acquired a new stake in shares of Vanda Pharmaceuticals during the 4th quarter worth about $17,626,000. Renaissance Technologies LLC boosted its stake in shares of Vanda Pharmaceuticals by 11.2% during the 1st quarter. Renaissance Technologies LLC now owns 3,759,559 shares of the biopharmaceutical company’s stock worth $25,979,000 after purchasing an additional 378,598 shares during the last quarter. Finally, Inscription Capital LLC grew its holdings in shares of Vanda Pharmaceuticals by 293.5% during the fourth quarter. Inscription Capital LLC now owns 63,878 shares of the biopharmaceutical company’s stock worth $563,000 after buying an additional 47,646 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Analyst Ratings Changes

VNDA has been the subject of a number of analyst reports. B. Riley Financial reissued a “buy” rating and issued a $12.00 price objective (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. HC Wainwright lowered their target price on shares of Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Wall Street Zen downgraded Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Vanda Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $13.70.

Vanda Pharmaceuticals Stock Up 2.1%

Shares of NASDAQ VNDA opened at $5.44 on Wednesday. Vanda Pharmaceuticals Inc. has a 52-week low of $4.27 and a 52-week high of $9.94. The firm has a fifty day moving average of $5.59 and a 200-day moving average of $6.53. The stock has a market capitalization of $328.90 million, a PE ratio of -1.17 and a beta of 0.64. The company has a quick ratio of 1.60, a current ratio of 1.61 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.46). Vanda Pharmaceuticals had a negative return on equity of 49.81% and a negative net margin of 127.41%.The firm had revenue of $50.53 million during the quarter, compared to analysts’ expectations of $61.92 million. On average, analysts anticipate that Vanda Pharmaceuticals Inc. will post -3 EPS for the current year.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.